Patents by Inventor David A. Bumcrot

David A. Bumcrot has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CRISPR/CAS-related methods and compositions for treating leber's congenital amaurosis 10 (LCA10)
    Patent number: 9938521
    Abstract: CRISPR/CAS-related compositions and methods for treatment of Leber's Congenital Amaurosis 10 (LCA10) are disclosed.
    Type: Grant
    Filed: March 10, 2015
    Date of Patent: April 10, 2018
    Assignee: EDITAS MEDICINE, INC.
    Inventors: Morgan L. Maeder, David A. Bumcrot, Shen Shen
  • Serpina1 siRNAs: compositions of matter and methods of treatment
    Patent number: 9879261
    Abstract: The technology described herein relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the Serpina1 gene, and methods of using such dsRNA compositions to inhibit expression of Serpina1.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: January 30, 2018
    Assignee: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Alfica Sehgal, David Bumcrot, Brian Bettencourt
  • CRISPR/CAS-RELATED METHODS AND COMPOSITIONS FOR TREATING SICKLE CELL DISEASE
    Publication number: 20170314015
    Abstract: CRISPR/CAS-related compositions and methods for treatment of Sickle Cell Disease (SCD) are disclosed.
    Type: Application
    Filed: March 26, 2015
    Publication date: November 2, 2017
    Inventors: Ari E. FRIEDLAND, Morgan L. MAEDER, G. Grant WELSTEAD, David A. BUMCROT
  • THERAPEUTIC COMPOSITIONS
    Publication number: 20170283801
    Abstract: This application relates to therapeutic siRNA agents and methods of making and using the agents.
    Type: Application
    Filed: June 14, 2017
    Publication date: October 5, 2017
    Inventors: Muthiah MANOHARAN, Kallanthottathil G. RAJEEV, David BUMCROT
  • GNAQ TARGETED dsRNA COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION
    Publication number: 20170240890
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting a G-alpha q subunit (GNAQ) of a heterotrimeric G gene, and methods of using the dsRNA to inhibit expression of GNAQ.
    Type: Application
    Filed: December 21, 2016
    Publication date: August 24, 2017
    Inventors: Jared Gollob, Gregory Hinkle, Ivanka Toudjarska, David Bumcrot
  • Therapeutic compositions
    Patent number: 9708615
    Abstract: This application relates to therapeutic siRNA agents and methods of making and using the agents.
    Type: Grant
    Filed: November 17, 2015
    Date of Patent: July 18, 2017
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Muthiah Manoharan, Kallanthottathil G. Rajeev, David Bumcrot
  • CRISPR-CAS-RELATED METHODS, COMPOSITIONS AND COMPONENTS FOR CANCER IMMUNOTHERAPY
    Publication number: 20170175128
    Abstract: CRISPR/Cas-related composition and methods for treatment of cancer, in particular by using gRNA molecules comprising a targeting domain which is complementary with a target domain from the FAS, BID, CTLA4, PDCD1, CBLB, PTPN6, TRAC or TRBC gene. In some embodiments, gRNAs are used with Cas9 enzymes to cause a cleavage event in said genes within engineered chimeric antigen receptor (CAR) T cells. In some embodiments, CAR T cells are modified to reduce, decrease or repress expression of said genes using gRNAs and Cas9 enzymes; said modified CAR T-cells are meant for therapeutic uses, especially for cancer.
    Type: Application
    Filed: April 17, 2015
    Publication date: June 22, 2017
    Inventors: G. Grant WELSTEAD, Ari E. FRIEDLAND, Morgan L. MAEDER, David A. BUMCROT
  • CRISPR/CAS-RELATED METHODS AND COMPOSITIONS FOR TREATING USHER SYNDROME AND RETINITIS PIGMENTOSA
    Publication number: 20170073674
    Abstract: CRISPR/Cas-related compositions and methods for treatment of Usher Syndrome and/or Retinitis Pigmentosa are disclosed herein.
    Type: Application
    Filed: March 5, 2015
    Publication date: March 16, 2017
    Inventors: Morgan L. MAEDER, David A. BUMCROT
  • CRISPR/CAS-RELATED METHODS AND COMPOSITIONS FOR TREATING HERPES SIMPLEX VIRUS TYPE 1 (HSV-1)
    Publication number: 20170073685
    Abstract: CRISPR/CAS-related compositions and methods for treatment of HSV-1 are disclosed.
    Type: Application
    Filed: September 30, 2016
    Publication date: March 16, 2017
    Inventors: Morgan L. Maeder, Ari E. Friedland, Grant G. Welstead, David A. Bumcrot
  • GNAQ targeted dsRNA compositions and methods for inhibiting expression
    Patent number: 9566295
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting a G-alpha q subunit (GNAQ) of a heterotrimeric G gene, and methods of using the dsRNA to inhibit expression of GNAQ.
    Type: Grant
    Filed: October 6, 2014
    Date of Patent: February 14, 2017
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Jared Gollob, Gregory Hinkle, Ivanka Toudjarska, David Bumcrot
  • CRISPR/CAS-RELATED METHODS AND COMPOSITIONS FOR TREATING PRIMARY OPEN ANGLE GLAUCOMA
    Publication number: 20170029850
    Abstract: CRISPR/CAS-related compositions and methods for treatment of Primary Open Angle Glaucoma (POAG) are disclosed.
    Type: Application
    Filed: April 1, 2015
    Publication date: February 2, 2017
    Inventors: Morgan L. MAEDER, David A. BUMCROT
  • CRISPR/CAS-RELATED METHODS AND COMPOSITIONS FOR TREATING CYSTIC FIBROSIS
    Publication number: 20170022507
    Abstract: CRISPR/CAS-related compositions and methods for treatment of Cystic Fibrosis (CF).
    Type: Application
    Filed: October 7, 2016
    Publication date: January 26, 2017
    Applicant: EDITAS MEDICINE, INC.
    Inventors: Deepak Reyon, Morgan L. Maeder, Ari E. Friedland, Grant G. Welstead, David A. Bumcrot
  • CRISPR/CAS-RELATED METHODS AND COMPOSITIONS FOR TREATING HIV INFECTION AND AIDS
    Publication number: 20170007679
    Abstract: CRISPR/CAS-related compositions and methods for treatment of a subject at risk for or having a HIV infection or AIDS are disclosed.
    Type: Application
    Filed: September 23, 2016
    Publication date: January 12, 2017
    Applicant: EDITAS MEDICINE INC.
    Inventors: Morgan L. Maeder, Ari E. Friedland, G. Grant Welstead, David A. Bumcrot
  • SERPINA1 SIRNAS: COMPOSITIONS OF MATTER AND METHODS OF TREATMENT
    Publication number: 20160244752
    Abstract: The technology described herein relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the Serpina1 gene, and methods of using such dsRNA compositions to inhibit expression of Serpina1.
    Type: Application
    Filed: December 18, 2015
    Publication date: August 25, 2016
    Applicant: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Alfica SEHGAL, David BUMCROT, Brian BETTENCOURT
  • COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF TMPRSS6 GENE
    Publication number: 20160145626
    Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the TMPRSS6 gene, and methods of using such dsRNA compositions to inhibit expression of TMPRSS6.
    Type: Application
    Filed: September 25, 2015
    Publication date: May 26, 2016
    Applicant: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: David A. Bumcrot, Brian Bettencourt, Ivanka Toudjarska
  • THERAPEUTIC COMPOSITIONS
    Publication number: 20160076040
    Abstract: This application relates to therapeutic siRNA agents and methods of making and using the agents.
    Type: Application
    Filed: November 17, 2015
    Publication date: March 17, 2016
    Inventors: Muthiah MANOHARAN, Kallanthottathil G. RAJEEV, David BUMCROT
  • Compositions and Methods for Inhibiting Expression of Eg5 Gene
    Publication number: 20160017337
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the Eg5 gene (Eg5 gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the Eg5 gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by Eg5 expression and the expression of the Eg5 gene using the pharmaceutical composition; and methods for inhibiting the expression of the Eg5 gene in a cell.
    Type: Application
    Filed: May 22, 2015
    Publication date: January 21, 2016
    Inventors: David Bumcrot, Pamela Tan, Hans-Peter Vornlocher, Anke Geick
  • Compositions and Methods for Inhibiting Expression of Eg5 and VEGF Genes
    Publication number: 20160000819
    Abstract: This invention relates to compositions containing double-stranded ribonucleic acid (dsRNA) in a SNALP formulation, and methods of using the compositions to inhibit the expression of the Eg5 and Vascular Endothelial Growth Factor (VEGF), and methods of using the compositions to treat pathological processes mediated by Eg5 and VEGF expression, such as cancer.
    Type: Application
    Filed: April 9, 2015
    Publication date: January 7, 2016
    Inventors: David Bumcrot, Dinah Wen-Yee Sah, Ivanka Toudjarska
  • Therapeutic compositions
    Patent number: 9222091
    Abstract: This application relates to therapeutic siRNA agents and methods of making and using the agents.
    Type: Grant
    Filed: May 20, 2014
    Date of Patent: December 29, 2015
    Assignee: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Muthiah Manoharan, Kallanthottathil G. Rajeev, David Bumcrot
  • Compositions and methods for inhibiting expression of TMPRSS6 gene
    Patent number: 9175290
    Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the TMPRSS6 gene, and methods of using such dsRNA compositions to inhibit expression of TMPRSS6.
    Type: Grant
    Filed: March 28, 2012
    Date of Patent: November 3, 2015
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: David Bumcrot, Brian Bettencourt, Ivanka Toudjarska